Achillion Pharmaceuticals, Inc. (ACHN) financial statements (2020 and earlier)

Company profile

Business Address 300 GEORGE STREET
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1543549503635304
Cash and cash equivalents44354950363537
Short-term investments110     267
Restricted cash and investments0      
Receivables   1   
Prepaid expense   0   
Other undisclosed current assets42032102242502576
Total current assets:158238259275286292310
Noncurrent Assets
Operating lease, right-of-use asset2  
Property, plant and equipment1122233
Long-term investments and receivables75     3
Long-term investments75     3
Restricted cash and investments 000000
Other noncurrent assets0000000
Other undisclosed noncurrent assets 92  8 
Total noncurrent assets:7911423116
TOTAL ASSETS:236248263278289303316
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17151212888
Accounts payable3522212
Accrued liabilities1411109776
Debt1  0000
Other undisclosed current liabilities 11    
Total current liabilities:18161312988
Noncurrent Liabilities
Long-term debt and lease obligation2   000
Long-term debt, excluding current maturities    000
Operating lease, liability2  
Liabilities, other than long-term debt   0000
Deferred revenue and credits0
Deferred rent credit   000 
Other undisclosed noncurrent liabilities 11    
Total noncurrent liabilities:2110000
Total liabilities:19171412988
Stockholders' equity
Stockholders' equity attributable to parent217232249266281295307
Common stock0000000
Additional paid in capital948943941939937935931
Accumulated other comprehensive income (loss)000(0)(0)(0)(1)
Accumulated deficit(731)(711)(692)(673)(656)(640)(623)
Total stockholders' equity:217232249266281295307
TOTAL LIABILITIES AND EQUITY:236248263278289303316

Income statement (P&L) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Operating expenses(21)(21)(21)(18)(17)(19)(22)
Operating loss:(21)(21)(21)(18)(17)(19)(22)
Nonoperating income
(Investment Income, Nonoperating)
1222111
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(20)(19)(19)(17)(16)(17)(21)

Comprehensive Income ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net loss:(20)(19)(19)(17)(16)(17)(21)
Other comprehensive income (loss)(0)00    
Other undisclosed comprehensive income   0   
Comprehensive loss:(20)(19)(19)(16)(16)(17)(21)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   (0)00(0)
Comprehensive loss, net of tax, attributable to parent:(20)(19)(19)(17)(16)(17)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: